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ScienceDirectThis review discusses advances in understanding how the
controlled delivery of cholesterol between subcellular
compartments is achieved and what novel experimental
strategies are being employed to address this fundamental
question. Recent work has focused on cholesterol-binding
proteins that can facilitate directional cholesterol transfer
between contacts of the ER and Golgi or late endosomal
membranes. Increasing structural information on cholesterol-
binding proteins, new modules engineered from them as well
as improved imaging and gene editing techniques are providing
valuable insights. There is also mounting information on how
the crosstalk between cholesterol transport and nutrient
signaling is orchestrated and how cellular fatty acid metabolism
and cholesterol homeostasis are intertwined.
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Introduction
Cholesterol is an essential component of mammalian cell
membranes. It is unevenly distributed between mem-
branes (Figure 1) and rapidly exchanged between them.
This article aims to briefly summarize interesting obser-
vations made during the past couple of years in the field of
cellular cholesterol trafficking and homeostasis, and to
point towards emerging trends. Increasing evidence sug-
gests that besides membrane transport, lipid transfer
proteins provide specific paths of cholesterol exchange
between closely apposed membranes. Advances have
been made, for example, in understanding late endosomal
cholesterol transport, ER-to-Golgi sterol delivery and
links between cholesterol transport, nutrient signaling
and fatty acid metabolism. Moreover, improved tools
such as biosensors deriving from cholesterol-bindingwww.sciencedirect.com protein modules have been employed for probing choles-
terol compartmentalization. For further information on
the topic, the reader is referred to more comprehensive
reviews [1–5].
Late endosomal cholesterol binding proteins:
the usual suspects in cholesterol transport
A major route of cholesterol entry into mammalian cells is
via endocytosis of low density lipoproteins (LDL). Upon
release from the LDL receptor and acid hydrolysis of the
particle contents, the released cholesterol is removed
from late endosomal organelles via the co-ordinated
action of Niemann–Pick type C (NPC) 1 (NPC1) and
NPC2 proteins. During the past few years, increasing
structural information on NPC1 has revealed insights into
the architecture of this complex protein with 13 mem-
brane spans, including luminal interaction with NPC2
and Ebola virus [6–8], membrane embedded sterol-sens-
ing domain [9] and C-terminal luminal domain [10].
Despite these developments, how cholesterol reaches the
lysosomal limiting membrane remains mysterious. Cho-
lesterol somehow traverses the 8 nm thick lysosomal
glycocalyx and the heavily glycosylated, abundant lyso-
somal membrane proteins LAMPs that can also bind
cholesterol, play a role [11,12]. Indeed, cholesterol can
bind to protein domains located at a considerable distance
(12 Å) from the membrane spanning region, as shown, for
example, for the extracellular domain of Smoothened
[13]. However, also in this case the mechanism by which
cholesterol gains access to this binding pocket is
unknown.
From lysosomes, LDL-derived cholesterol is delivered to
other membrane compartments. Recent findings argue
that the bulk of LDL-cholesterol is transported to the
plasma membrane, to replenish this cholesterol pool(s)
[14,15]. One of the regulators of this route is Rab8a that is
recruited in an NPC1-dependent manner to cholesterol-
enriched late endosomal organelles and promotes their
delivery to the leading edge of the cell [16]. Remarkably,
in the absence of functional NPC1, the therapeutic drug
candidate b-cyclodextrin can induce subplasmalemmal
redistribution of the storage lysosomes and their subse-
quent release to the extracellular space [17].
The mechanisms of post-NPC1 cholesterol trafficking to
the ER remain puzzling, despite the tantalizing presence
of cytoplasmically oriented cholesterol-binding and ER
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Subcellular compartmentalization of cholesterol. Primary human fibroblasts were grown in complete medium and sterol detected by filipin or
BODIPY-cholesterol. (a) Cholesterol is enriched in the plasma membrane, where it represents about 30–40 mol% of lipids. Plasma membrane
protrusions are often cholesterol enriched. Please note a tunneling nanotube connecting two cells (white arrowheads) and plasma membrane
derived vesicles/blebs, typical for fibroblast cultures (empty arrowhead). The ER extends throughout the cell but its cholesterol content is low
(typically 3–6 mol% of lipids) and not visualized by filipin (dotted line). The cholesterol content of the Golgi complex is intermediate between ER
and plasma membrane, increasing in cis-to-trans direction. (b) Overlay of filipin staining in A with anti-TGN46 antibody staining. The cholesterol
content of endo-lysosomal organelles varies considerably pending on incoming lipoprotein cholesterol uptake. (c) Overlay of filipin and anti-Lamp1
staining. (d) Cells labeled overnight with dextran and BODIPY-cholesterol. Please note BODIPY-cholesterol perinuclear Golgi-like labeling and
partial colocalization with dextran-positive lysosomes.
Source: Images courtesy of Maarit Hölttä-Vuori, stainings and imaging performed as in Refs. [20,37].proteins [3,4]. In particular, the ORP1L and STARD3
proteins can bind VAP in the ER, bridging between late
endosomes and the ER. Interestingly, recent reports
provide evidence that both ORP1L and STARD3 trans-
fer cholesterol to the opposite direction, that is, from
the ER to endosomes, employing VAP as the ER partner
[18,19]. STARD3 expression induces cholesterol accu-
mulation in endosomes and favours the formation of
pleomorphic membrane structures inside endosomes
[19]. This is in line with earlier findings that dehydroer-
gosterol (DHE) accumulates in late endosomes expres-
sing STARD3 [20].
The ORP1L–VAP interaction is needed for ER-endo-
some cholesterol transport under low-cholesterol condi-
tions, to support intraluminal vesicle formation in the
endosome lumen [18]. Accordingly, multivesicular body
formation was reported to depend on cholesterol and
ORP1L [21]. Furthermore, ORP1L–VAP interactions
can establish contacts between the ER and late autopha-
gosomes under low-cholesterol conditions [22]. These
data fit with the idea that ORP1L–VAP affinity isCurrent Opinion in Cell Biology 2018, 53:77–83 increased when ORP1L is not sterol bound [23–25].
However, this is not as easy to reconcile with a model
where ORP1L mediates cholesterol egress from the
endo-lysosomal system under the high endosomal cho-
lesterol conditions induced by LDL loading [26].
Nevertheless, under some conditions ORP1L facilitates
cholesterol transfer towards the ER. Upon acute adeno-
viral infection the viral RIDa protein hijacks the ORP1L
sterol-binding domain and apparently induces a novel
trafficking route [27]. On the whole, the specialized roles
of vesicle subpopulations [28] and dynamic communica-
tion between membranes that influences endosome
motility, fission, and cargo trafficking are becoming
increasingly apparent [29]. In this scenario proteins
may not only be recycled but also repurposed, pending
on the metabolic cues and local co-incidence of other
machinery components.www.sciencedirect.com
Mechanisms of cellular cholesterol transport Ikonen 79Role of OSBP in ER–Golgi cholesterol
transport
The ER receives cholesterol from the plasma membrane,
other endomembranes and via de novo synthesis. Yet, the
ER cholesterol content is kept low (normally a few mol
% of lipids, Figure 1), necessitating efficient cholesterol
export. One of the proteins topologically suited for this
task is OSBP with its pH domain binding PI4P in the
TGN, FFAT motif binding VAP in the ER and ORD
domain capable of binding and transferring cholesterol.
This model, first assessed in vitro with purified compo-
nents [30], was recently verified in mammalian cells,
taking advantage of the compound OSW-1 to rapidly
switch off endogenous OSBP [31]. A 2-h treatment
with the drug was accompanied by reduced DHE labeling
in the TGN and increased labeling in lipid droplets,
suggesting altered ratio between forward and backward
sterol movement between the late and early secretory
pathway.
PI4P in the TGN was consumed by OSBP via exchange
against sterol and thus necessitating continuous replen-
ishment by PI4-kinase. Interestingly, the ER-TGN con-
tact sites were apparently driven by the kinase and were
highly dynamic, moving pending on enzyme activity,
with OSBP following. Notably, a 3-day silencing of OSBP
resulted in DHE redistribution from the TGN not to lipid
droplets but to late endosomal structures, speaking for
some compensatory effects manifesting at longer time
points [31]. This is important to keep in mind when
chronically depleting components from well safeguarded
machineries. At least in this case, a few days seemed
sufficient to induce such effects.
Widening perspectives: cholesterol transport,
nutrient signaling and fatty acid metabolism
There are also increasing insights into the interplay
between cholesterol homeostasis and nutrient signaling
via the master nutrient sensor mTORC1. Castellano
et al. studied the effects of cholesterol at the level of late
endosomal organelles and provided evidence for a dual
regulation of mTORC1 via LDL-derived cholesterol
[32]. Cholesterol activates mTORC1 via interaction
with the putative amino acid transporter SLC38A9. On
the other hand, NPC1 interacts with SLC38A9 and med-
iates mTORC1 inhibition under cholesterol starvation
conditions. This activity of NPC1 is abolished in the
sterol-sensing domain mutant NPC1-P691S, implicating
that it is somehow linked to the sterol sensing/transfer
function of NPC1.
In another line of investigation, Zha and coworkers found
that mTORC1 activity is required to maintain endosomal
recycling and to prevent lysosomal delivery of recycling
receptors and membrane lipids [33]. Interestingly,
mTORC1 also controls SREBP-2 via this membrane
routing: as high mTORC1 activity maintains endosomalwww.sciencedirect.com recycling and suppresses autophagy, less (recycling and
autophagosomal) membrane-derived cholesterol is traf-
ficking to lysosomes. This, in turn, keeps ER cholesterol
low and SREBP-2 active. An intriguing issue is why the
increased flow of cholesterol to the plasma membrane is
not reflected as increased cholesterol delivery to the ER
and consequent inactivation of SREBP-2. This could be
related to the high potential of the plasma membrane to
sequester cholesterol [34] and/or to the analysis time
point after refeeding.
Recent elegant work using in vivo models highlights how
cholesterol compartmentalization is critically affected by
other membrane lipids. Endogenous fatty acid synthesis
in macrophages plays an important role in controlling
cellular cholesterol distribution and metabolism. In fatty
acid synthase (FAS) deficient macrophages, the choles-
terol content was decreased and cholesterol was more
readily released from the plasma membrane [35]. More-
over, the production of endogenous fatty acids was nec-
essary for the assembly of cholesterol-dependent inflam-
matory signaling networks at the plasma membrane,
modulating inflammation and insulin resistance at the
whole-body level.
Mechanistically, the effect of fatty acids may be medi-
ated, for example, via the acyl chain composition of
phospholipids. For instance, the structure of phosphati-
dylcholine has been shown to influence SREBP-1 proces-
sing via the SCAP pathway. The phospholipid remodel-
ling enzyme LPCAT3 drives the incorporation of
polyunsaturated fatty acids in the ER, and by promoting
the generation of PC with 2 or 4 double bonds in the fatty
acids (linoleyl or arachidonoyl PC), stimulates SREBP-1
maturation [36].
Sharpening tools for cholesterol detection
Optimally, cholesterol trafficking would be visualized
conveniently by imaging at high subcellular resolution.
With the current tools, this remains a challenge. Both the
fluorescent sterols and sterol-binding protein domains
employed for the purpose have caveats, but there is
increasing awareness of their applications/limitations,
and improvements have been made.
As an example, in the case of BODIPY-cholesterol
(TopFluor-Cholesterol) both the method of delivery
and analysis time point affect the distribution. When
administered from solvent, sterol sequestration charac-
teristic of a lysosomal storage disease becomes evident
only after equilibration with membranes [37]. DHE that
is structurally more similar to cholesterol (Figure 2), has
suboptimal fluorescence properties (UV excitation, rapid
bleaching). Yet, improved optics and cameras enabled
more accurate measurements, leading to the re-estima-
tion of the rate of sterol transport between the endocytic
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Select cholesterol binding proteins and fluorescent sterols used for studying cholesterol compartmentalization. (a) Bacterial cholesterol-dependent
cytolysins kill cells by binding to the 3-OH groups of cholesterol molecules and oligomerizing to generate a membrane pore. Cryo-electron
tomographic structure of pneumolysin (adapted from Ref. [51]). (b) The juxtamembrane D4 domain binds cholesterol, shown for perfringolysin O
(adapted from Ref. [52]). (c) Schematic structure of the inducible split cholesterol oxidase, with the N-terminal fragment in blue and C-terminal
fragment in green (from [46]). (d) Structures of two fluorescent sterol analogs. The differences to cholesterol are indicated with blue
(dehydroergosterol) or green (BODIPY-cholesterol, a.k.a. TopFluor-cholesterol).measured t1/2 = 12–15 min) and the conclusion that
STARD4 accounts for 1/4 of this transport [38]. Inter-
estingly, a 20% increase in cellular cholesterol content
had a major kinetic effect, increasing the DHE transport
rate 3–4-fold.
The domain 4 (D4) of the bacterial toxin perfringolysin O
(PFO) or anthrolysin O (ALO) has been developed as a
cholesterol-biosensor. D4 is a 13 kDa protein that recog-
nizes the 3-OH group of cholesterol when present at
30 mol% or higher (Figure 2). The higher affinity variant
D4H has a slightly lower threshold for cholesterol [39].
Importantly, a recent study characterized additional point
mutants of PFO D4, including mutants that can recognize
a range of cholesterol concentrations to as low as 1 mol%
[40]. These fluorescently labeled biosensors were
applied extracellularly or to the cytoplasm (via microin-
jection) into commonly used cell types and membrane
bindings were recorded.
Based on the results, the exofacial leaflets were estimated
to contain 30–40 mol% and cytosolic leaflets 2–5 mol% of
cholesterol. Interestingly, ABCA1 and ABCG1 wereCurrent Opinion in Cell Biology 2018, 53:77–83 shown to maintain the low cholesterol concentration in
the inner plasma membrane leaflet, whereas knockdown
of NPC1, ORP5 or STARD4 did not affect the transbi-
layer distribution of cholesterol [40]. However, it is
worth noting that the transbilayer distribution of choles-
terol remains controversial. According to other estimates,
cholesterol may rather be enriched in the inner leaflet [41]
or be homogeneously distributed between leaflets [42].
Although no probes come without pitfalls, the strategy
and observations by Liu et al. [40] represent the most
sophisticated assessment of cholesterol transbilayer dis-
tribution so far. With high spatial imaging resolution,
these sterol-binding probes may also give insights into
the lateral distribution of cholesterol. For instance, nano-
scale secondary ion mass spectrometric imaging of D4
domains demonstrated that the accessible cholesterol was
highly enriched in microvilli [43].
Indeed, cholesterol-binding protein domains bind to the
accessible fraction of cholesterol, that is, the fraction that
is capable of interacting with water-soluble molecules at
the surface and is not shielded due to associations with
neighboring lipids (see e.g. [44]). Another obvious caveatwww.sciencedirect.com
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may modify its partitioning in the membrane and
between membranes. Infante and Radhakrishnan took
advantage of this behaviour of ALO D4, employing it as
an inhibitor of cholesterol transport from the plasma
membrane to the ER. Using this approach, they con-
cluded that LDL-cholesterol moves initially from lyso-
somes to the PM, and subsequently to the ER to suppress
activation of SREBPs [15]. It has also been noted that D4
binding is not necessarily a suitable measure of the
membrane cholesterol content, especially when compar-
ing different kinds of cells or membranes. For example,
D4 cholesterol accessibility in human erythrocytes varied
over 10-fold among individuals and this was unrelated to
the membrane cholesterol content but rather associated
with the phospholipid composition [45].
Another bacteria-derived tool in cholesterol research is
cholesterol oxidase that hydrolyzes the 3-OH group to
produce cholestenone. One of the issues hampering its
cell biological use is high efficiency and thereby toxicity.
To improve the controllability and tracking of the
enzyme, a split, rapamycin-inducible fluorescent choles-
terol oxidase was recently engineered [46] (Figure 2).
When the split halves are introduced into human cells,
rapamycin allows temporal control of the enzyme activity,
with initiation of oxidation upon addition of the drug and
loss of enzyme expression with concomitant recovery of
cholesterol levels upon its removal.
Concluding remarks
Advances in the field of cholesterol trafficking are not
effortless, due to the complexity of lipid metabolic regu-
lation, but are stimulated by the privilege of standing on
the shoulders of giants (see e.g. [5]). The ongoing devel-
opment of novel tools and experimental strategies pro-
vide incentives to keep up with the high standards.
Progress is to be expected for instance in structure–
function relationships of cholesterol-interacting proteins
and in harnessing lipid transport and metabolism by
editing endogenous cellular proteins.
As exemplified in the case of NPC1 protein, the upsurge
in protein structural analysis by X-ray crystallography and
cryo-electron microscopy is starting to reveal atomic-level
insights into how cholesterol interacts with proteins and
influences their behaviour. Moreover, important proteins
controlling cholesterol transport and distribution in mam-
malian cells most probably still remain to be character-
ized, as suggested by the identification of mammalian
proteins in the LAM (lipid transfer proteins anchored at
membrane contact sites) family that contain StART-like
lipid transfer domains and are capable of transferring
cholesterol [47,48].
In the cellular context, robust overexpression or chronic
knockout of a protein is rarely an optimal strategy,www.sciencedirect.com especially when a protein is part of a large interlinked
network, as in lipid homeostatic regulation. For instance,
it has been known for 10 years that the cholesterol
threshold of 5 mol% ER lipids — that inhibits SREBP-
2 export from the ER — becomes 3 mol% when cells
express elevated amounts of Insig-1 [49]. Besides shifting
the balance between protein functions, persistent protein
manipulation often leads to compensatory changes that
abolish or mitigate the primary perturbation.
CRISPR/Cas9 based gene editing has introduced a major
paradigm shift in this area. It is now feasible to study
proteins expressed from their endogenous loci, introduc-
ing tags that facilitate rapid re-localization in cells, target-
ing for degradation, affinity capture, and so on — pending
that the tag does not perturb the protein function. More-
over, increasingly elegant screens utilizing CRISPR/Cas9
based approaches are within reach, as shown, for example,
by the recent identification of a novel E3 ligase regulating
HMGCR degradation and cholesterol biosynthesis [50].
Together with the ongoing development of cholesterol
detection methods and structural information on protein–
lipid interactions, these tools are helping to reveal novel
players in cholesterol compartmentalization.
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